Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flamenco: Fluzoparib as Adjuvant Treatment in HRR Mutated Primary Breast Cancer
NCT07353437Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Mar 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of fluzoparib in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 3 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07353437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353437.